Alternative Data for Genelux
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 496 | Sign up | Sign up | Sign up |
| X Followers | 134 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 34 | Sign up | Sign up | Sign up |
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
| Price | $2.63 |
| Target Price | Sign up |
| Volume | 134,535 |
| Market Cap | $125M |
| Year Range | $2.35 - $8.24 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Animal Health Partnering Terms and Agreements Report 2026 with Directory of 280 Deals Signed Since 2017 by Company A-Z, Technology Type, Therapy Area, and Development StageMarch 12 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -8M | -7.8M | -0.210 |
| Q2 '25 | 0 | 140,000 | -140,000 | -7.5M | -7.3M | -0.200 |
| Q1 '25 | 450,000 | 140,000 | -140,000 | -7.5M | -7.7M | -0.210 |
| Q4 '24 | 900,000 | 450,000 | -230,000 | -9M | -8.7M | -0.250 |
| Q3 '24 | 0 | 220,000 | -220,000 | -6.5M | -6.2M | -0.190 |
Insider Transactions View All
| Thomas John filed to sell 482,784 shares at $2.9. March 3 '26 |
| Smalling Ralph filed to sell 68,658 shares at $4.7. December 9 '25 |
| Thomas John filed to sell 492,784 shares at $5. December 2 '25 |
| Smalling Ralph filed to sell 68,823 shares at $5.4. December 9 '25 |
| Cappello Joseph filed to sell 156,060 shares at $5.4. December 11 '25 |
Similar companies
Read more about Genelux (GNLX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Genelux
The Market Cap of Genelux is $125M.
Currently, the price of one share of Genelux stock is $2.63.
The GNLX stock price chart above provides a comprehensive visual representation of Genelux's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Genelux shares. Our platform offers an up-to-date GNLX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Genelux (GNLX) does not offer dividends to its shareholders. Investors interested in Genelux should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Genelux are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
